SLEDAI-2K does not conceal worsening in a particular system when there is overall improvement

Journal of Rheumatology

Volumn 42, Issue 8, 2015, Pages 1401-1405

  Touma, Zahi ^a   Gladman, Dafna D ^a,b   Su, Jiandong ^a   Ibañez, Dominique ^a   Urowitz, Murray B ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Disease activity; SLEDAI 2K; Systemic lupus erythematosus

Indexed keywords

COMPLEMENT; DNA ANTIBODY; HEMOGLOBIN;

ABNORMAL LABORATORY RESULT; ADULT; ALOPECIA; ANEMIA; ARTHRITIS; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; COMPLEMENT DISORDER; COOMBS POSITIVE HEMOLYTIC ANEMIA; DETERIORATION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; HEMATOLOGIC DISEASE; HEMATURIA; HUMAN; IMMUNOPATHOLOGY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; PATIENT CODING; PRIORITY JOURNAL; PROTEINURIA; PYURIA; RASH; REMISSION; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; URINARY CAST; VASCULITIS; ADOLESCENT; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT; YOUNG ADULT;

ADOLESCENT; ADULT; DISEASE PROGRESSION; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT; YOUNG ADULT;

EID: 84940707629     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.141088     Document Type: Article

References (17)

1. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
2. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D, et al. Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol 1992;19:608-11.
3. Hawker G, Gabriel S, Bombardier C, Goldsmith C, Caron D, Gladman D. A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus. J Rheumatol 1993;20:657-60.
4. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D, et al. Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. J Rheumatol 1994;21:1468-71.
5. Gladman DD, Ibaez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
6. Ibaez D, Gladman DD, Touma Z, Nikpour M, Urowitz MB. Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time. J Rheumatol 2011;38:60-3.
7. Touma Z, Urowitz MB, Ibaez D, Gladman DD. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus 2011;20:67-70.
8. Touma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day window. Lupus 2010;19:49-51.
9. Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51.
10. Wallace DJ, Gordon C, Strand V, Hobbs K, Petri M, Kalunian K, et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology 2013;52:1313-22.
11. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
12. Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol 2000;27:377-9.
13. Lohr KN, Aaronson NK, Alonso J, Burnam MA, Patrick DL, Perrin EB, et al. Evaluating quality-of-life and health status instruments: development of scientific review criteria. Clin Ther 1996;18:979-92.
14. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721-31.
15. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al; BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
16. Touma Z, Urowitz MB, Gladman DD. Systemic lupus erythematosus: an update on current pharmacotherapy and future directions. Expert Opin Biol Ther 2013;13:723-37.
17. Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al; BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012;71:1833-8.